Telectronics replacements for withdrawn Encor/Accufix pacer leads pending at FDA.
This article was originally published in The Gray Sheet
Executive SummaryTELECTRONICS REPLACEMENTS FOR ENCOR/ACCUFIX PACER LEADS are undergoing premarket review by FDA, the firm states. Two Maxim passive fixation (non-steroidal) atrial leads - one unipolar and one bipolar -- have been under 510(k) review by the agency since the applications were submitted in the first quarter, Telectronics says. A 510(k) also is pending for the firm's Secure active fixation (non-steroidal), bipolar, ventricular lead.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.
At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.